<div id="readability-page-1"><div><ul> <li>Roivant Sciences recently reported that Priovant has begun enrolling patients in a seamless Phase 2b/3 trial of brepocitinib for lichen planopilaris and released past topline Phase 3 data from Immunovant’s batoclimab thyroid eye disease studies, which did not meet their primary endpoint but showed consistent safety.</li> <li>The update underscores Roivant’s growing late-stage immunology pipeline, led by brepocitinib’s FDA Priority Review in dermatomyositis and multiple additional indications advancing in parallel.</li> <li>We will now examine how the launch of brepocitinib’s Phase 2b/3 LPP program may influence Roivant Sciences’ broader investment narrative.</li> </ul><p>Uncover the next big thing with 33 elite penny stocks that balance risk and reward.</p><h2>Roivant Sciences Investment Narrative Recap</h2><p>To own Roivant, you need to believe its immunology pipeline can convert late stage assets into meaningful commercial drugs despite ongoing losses and clinical risk. The key near term catalyst is the FDA Priority Review of brepocitinib in dermatomyositis, with the new LPP Phase 2b/3 start modestly reinforcing brepocitinib’s potential breadth rather than changing that focus. The biggest current risk remains late stage trial setbacks across this concentrated pipeline, which the batoclimab TED miss clearly illustrates.</p> <p>The most relevant recent announcement here is Priovant’s launch of the seamless Phase 2b/3 trial of brepocitinib in LPP, a painful scarring hair loss condition with no approved therapies. This program adds a fourth late stage indication on top of dermatomyositis, non infectious uveitis and cutaneous sarcoidosis, tightening the link between upcoming brepocitinib readouts and Roivant’s future earnings potential, but also increasing the operational and clinical execution risk around a single core asset.</p> <p>Yet beneath this expanding late stage story, investors should be aware of how trial failures or delays could quickly reshape expectations around Roivant’s...</p> <p>Read the full narrative on Roivant Sciences (it's free!)</p><p>Roivant Sciences’ narrative projects $1.4 billion revenue and $210.2 million earnings by 2029.</p><p>Uncover how Roivant Sciences' forecasts yield a $33.25 fair value, a 18% upside to its current price.</p><h2>Exploring Other Perspectives</h2> <p>Some of the most optimistic analysts, who once modeled revenue reaching about US$2.5 billion and earnings of roughly US$292.3 million by 2028, may reassess those targets after the mixed brepocitinib and batoclimab news, while you weigh how much late stage trial risk you are truly comfortable with.</p><p>Explore 3 other fair value estimates on Roivant Sciences - why the stock might be worth less than half the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Roivant Sciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Roivant Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Roivant Sciences' overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li><li>We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Roivant Sciences has initiated a Phase 2b/3 trial of brepocitinib for lichen planopilaris and released mixed results from batoclimab studies. The update highlights Roivant's expanding immunology pipeline, with brepocitinib's FDA Priority Review as a key catalyst. However, ongoing clinical risks and potential trial setbacks could impact investor expectations. Analysts may reassess revenue forecasts following the recent news, emphasizing the importance of understanding the associated risks before investing in Roivant Sciences.</p>

Simplywall

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Roivant Sciences

iShares Biotechnology ETF

VG Health

ALPS Medical Breakthrough

iShares Global Healthcare

VanEck Biotech ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

Is Brepocitinib’s LPP Trial And Mixed Batoclimab Data Altering The Investment Case For Roivant Sciences (ROIV)?